المؤلفون: Grimmelmann I., Momma M., Zimmer L., Hassel J. C., Heinzerling L., Pfohler C., Loquai C., Ruini C., Utikal J., Thoms K. -M., Kahler K. C., Eigentler T., Herbst R. A., Meier F., Debus D., Berking C., Kochanek C., Ugurel S., Gutzmer R.

المساهمون: Grimmelmann, I., Momma, M., Zimmer, L., Hassel, J. C., Heinzerling, L., Pfohler, C., Loquai, C., Ruini, C., Utikal, J., Thoms, K. -M., Kahler, K. C., Eigentler, T., Herbst, R. A., Meier, F., Debus, D., Berking, C., Kochanek, C., Ugurel, S., Gutzmer, R.

مصطلحات موضوعية: diabete, diabetes mellitu, immune checkpoint inhibitor, immune-related adverse event, ipilimumab, lipase, nivolumab, pancreatiti, pd-1 inhibitor, pembrolizumab, adult, aged, 80 and over, biomarker, blood glucose, type 1, exocrine pancreatic insufficiency, female, germany, human, male, melanoma, middle aged, predictive value of test, retrospective studie, skin neoplasm, time factor, treatment outcome, up-regulation, young adult

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33812141; info:eu-repo/semantics/altIdentifier/wos/WOS:000647678000001; volume:149; firstpage:1; lastpage:10; numberofpages:10; journal:EUROPEAN JOURNAL OF CANCER; https://hdl.handle.net/11573/1682141Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85105295200

الإتاحة: https://doi.org/10.1016/j.ejca.2021.02.017Test
https://hdl.handle.net/11573/1682141Test

المؤلفون: Grimmelmann I., Momma M., Zimmer L., Hassel J. C., Heinzerling L., Pfohler C., Loquai C., Ruini C., Utikal J., Thoms K. -M., Kahler K. C., Eigentler T., Herbst R. A., Meier F., Debus D., Berking C., Kochanek C., Ugurel S., Gutzmer R.

المساهمون: Grimmelmann, I., Momma, M., Zimmer, L., Hassel, J. C., Heinzerling, L., Pfohler, C., Loquai, C., Ruini, C., Utikal, J., Thoms, K. -M., Kahler, K. C., Eigentler, T., Herbst, R. A., Meier, F., Debus, D., Berking, C., Kochanek, C., Ugurel, S., Gutzmer, R.

مصطلحات موضوعية: Diabete, Diabetes mellitu, Immune checkpoint inhibitor, Immune-related adverse event, Ipilimumab, Lipase, Nivolumab, Pancreatiti, PD-1 inhibitor, Pembrolizumab, Adult, Aged, 80 and over, Biomarker, Blood Glucose, Diabetes Mellitus, Type 1, Exocrine Pancreatic Insufficiency, Female, Germany, Human, Male, Melanoma, Middle Aged, Predictive Value of Test, Retrospective Studie, Skin Neoplasm, Time Factor, Treatment Outcome, Up-Regulation

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33812141; info:eu-repo/semantics/altIdentifier/wos/WOS:000647678000001; volume:149; firstpage:1; lastpage:10; journal:EUROPEAN JOURNAL OF CANCER; http://hdl.handle.net/11380/1259113Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85105295200

الإتاحة: https://doi.org/10.1016/j.ejca.2021.02.017Test
http://hdl.handle.net/11380/1259113Test